TORONTO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) is pleased to announce…
ALPHARETTA, Ga., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to…
WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive…
- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE)…
Israeli patent covers a country known as a hotbed for medical device innovationSouthlake, Texas, Feb. 06, 2023 (GLOBE NEWSWIRE) --…
PALO ALTO, Calif., Feb. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento…
Vacaville high school students explore local career opportunities to honor National Career Technical Education Month Students at ICON Aircraft Students…
SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to…
SAN JOSE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- The Therapeutic Goods Administration (TGA) in Australia announced today that they…
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to…